Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
Anxiolytic Drugs: Benzodiazepines and Buspirone01:29

Anxiolytic Drugs: Benzodiazepines and Buspirone

Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Elucidating the Structural and Electronic Effects of Ni and Mn Cationic Incorporation on CoOOH for Efficient Benzyl Alcohol Electrooxidation.

ACS applied energy materials·2026
Same author

Pilot project paves way to storing CO<sub>2</sub> underground as minerals in arid countries.

Nature·2026
Same author

Correction: Effect of multiple calcination cycles on CO<sub>2</sub> capture efficiency during carbonation of MgO in a mineral looping process.

Scientific reports·2026
Same author

Mechanistic Insights into Defect-Mediated Crystallization Revealed by Lattice Strain Evolution.

Journal of the American Chemical Society·2026
Same author

From Pure to Seawater Electrolysis: Unveiling the Impact of Ionic Species and Contaminants on Electrocatalysis.

ACS electrochemistry·2026
Same author

Effect of multiple calcination cycles on CO<sub>2</sub> capture efficiency during carbonation of MgO in a mineral looping process.

Scientific reports·2025
Same journal

Impact of Omaveloxolone on Serum Lipids in Patients with Friedreich Ataxia: A 1-Year Real-World Analysis.

CNS drugs·2026
Same journal

Emerging Pharmacological Strategies for Trigeminal Neuralgia.

CNS drugs·2026
Same journal

Psychiatric Symptoms Associated with Corticosteroid Use: A Systematic Review and Meta-analysis.

CNS drugs·2026
Same journal

Anti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD.

CNS drugs·2026
Same journal

Isoform-Specific NaV Modulation in Painful Chemotherapy-Induced Neuropathy: Promise, Limitations, and a Clinical Agenda.

CNS drugs·2026
Same journal

Correction: Seletracetam Revisited: A Missed Opportunity for Effective Epilepsy Therapy.

CNS drugs·2026
See all related articles

Related Experiment Video

Updated: Jun 20, 2026

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats
05:12

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats

Published on: February 14, 2022

Asenapine.

Juliane Weber1, Paul L McCormack

  • 1Wolters Kluwer Health, Adis, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand.

CNS Drugs
|August 20, 2009
PubMed
Summary
This summary is machine-generated.

Asenapine effectively treats bipolar mania and schizophrenia symptoms, including negative symptoms in schizophrenia. This novel psychopharmacological agent demonstrated significant improvements in clinical assessments with generally mild side effects.

More Related Videos

A Surgical Procedure for the Administration of Drugs to the Inner Ear in a Non-Human Primate Common Marmoset (Callithrix jacchus)
06:55

A Surgical Procedure for the Administration of Drugs to the Inner Ear in a Non-Human Primate Common Marmoset (Callithrix jacchus)

Published on: February 27, 2018

Related Experiment Videos

Last Updated: Jun 20, 2026

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats
05:12

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats

Published on: February 14, 2022

A Surgical Procedure for the Administration of Drugs to the Inner Ear in a Non-Human Primate Common Marmoset (Callithrix jacchus)
06:55

A Surgical Procedure for the Administration of Drugs to the Inner Ear in a Non-Human Primate Common Marmoset (Callithrix jacchus)

Published on: February 27, 2018

Area of Science:

  • Psychopharmacology
  • Neuroscience

Background:

  • Asenapine is a novel psychopharmacological agent targeting dopamine, serotonin, noradrenaline, and histamine receptors.
  • It is under development for treating schizophrenia and bipolar mania.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of sublingual asenapine in adult patients with bipolar I disorder and acute schizophrenia.

Main Methods:

  • Conducted randomized, controlled trials for asenapine monotherapy and adjunctive therapy in bipolar I disorder.
  • Utilized clinician-assessed scales like the Young Mania Rating Scale (YMRS) and Positive and Negative Syndrome Scale (PANSS).
  • Assessed negative symptoms using the Negative Symptom Assessment (NSA-16) in schizophrenic patients over 26 weeks.

Main Results:

  • Sublingual asenapine significantly reduced YMRS scores in bipolar I disorder patients compared to placebo at 3 weeks.
  • Asenapine significantly reduced PANSS total scores in acute schizophrenia patients compared to placebo at 6 weeks.
  • Asenapine showed efficacy comparable to olanzapine in reducing negative symptoms of schizophrenia at 26 weeks.

Conclusions:

  • Sublingual asenapine is an effective treatment for acute mania in bipolar I disorder and acute schizophrenia.
  • It demonstrates efficacy in treating negative symptoms of schizophrenia.
  • Asenapine is generally well-tolerated, with a low incidence of significant adverse events like weight gain or extrapyramidal symptoms.